Kinetics of mycolactone in human subcutaneous tissue during antibiotic therapy for Mycobacterium ulcerans disease

Fred S Sarfo, Richard O Phillips, Jihui Zhang, Mohammed K Abass, Justice Abotsi, Yaw A Amoako, Yaw Adu-Sarkodie, Clive Robinson, Mark H Wansbrough-Jones, Fred S Sarfo, Richard O Phillips, Jihui Zhang, Mohammed K Abass, Justice Abotsi, Yaw A Amoako, Yaw Adu-Sarkodie, Clive Robinson, Mark H Wansbrough-Jones

Abstract

Background: Mycobacterium ulcerans (M. ulcerans) causes a devastating necrotising infection of skin tissue leading to progressive ulceration. M. ulcerans is the only human pathogen that secretes mycolactone, a polyketide molecule with potent cytotoxic and immunomodulatory properties. These unique features make mycolactone an attractive biomarker for M. ulcerans disease. We sought to measure the concentration of mycolactone within lesions of patients with Buruli ulcer before, during and after antibiotic treatment to evaluate its association with the clinical and bacteriological response to therapy.

Methods: Biopsies of M. ulcerans infected skin lesions were obtained from patients before, during and after antibiotic therapy. Lipids were extracted from the biopsies and concentration of mycolactone was assayed by mass spectrometry and a cytotoxicity assay and correlated with clinical and bacteriological response to therapy.

Results: Baseline concentration of mycolactone measured by mass spectrometry predicted time to complete healing of small nodules and ulcers. Even though intra-lesional concentrations of mycolactone declined with antibiotic treatment, the toxin was still present after antibiotic treatment for 6 weeks and also 4 weeks after the end of treatment for 8 weeks in a subgroup of patients with slowly healing lesions. Additionally viable bacilli were detected in a proportion of these slowly healing lesions during and after treatment.

Conclusions: Our findings indicate that baseline intra-lesional mycolactone concentration and its kinetics with antibiotic therapy are important prognostic determinants of clinical and bacteriological response to antibiotic treatment for Mycobacterium ulcerans disease. Mycolactone may be a useful biomarker with potential utility in optimising antibiotic therapy.

Figures

Figure 1
Figure 1
Mycolactone concentration in punch biopsies of untreated M. ulcerans disease lesions before antibiotic treatment. (A) Mycolactone concentration in ASL measured by cytotoxicity assay using synthetic mycolactone A/B generated calibration curves. Horizontal lines represent medians and each dot represents one lesion. (B) Mycolactone concentration in punch biopsies of untreated M. ulcerans disease lesions before antibiotic treatment. Mycolactone A/B concentration in ASL measured by multiple reaction monitoring (MRM) methodology with liquid chromatographic separation coupled to a tandem mass spectrometer. Horizontal lines represent medians and each dot represents one lesion.
Figure 2
Figure 2
Tissue mycolactone concentration in serial biopsies during and after antibiotic treatment. Antibiotic treatment was started at week 0 and completed at week 8. Biopsies were taken at weeks 0 in all patients and at week 6 and/or 12 when it was clinically indicated. (A) Mycolactone concentration in ASL measured by cytotoxicity assay using synthetic mycolactone A/B generated calibration curves. (B) Tissue mycolactone concentration in serial biopsies during and after antibiotic treatment. Mycolactone A/B concentration in ASL measured by multiple reaction monitoring (MRM) methodology with liquid chromatographic separation coupled to a tandem mass spectrometer.
Figure 3
Figure 3
Correlation between baseline mycolactone A/B concentration measured using mass spectrometry and time to complete healing. (A) All categories and forms of buruli lesion. (B) All category I lesions. (C) Nodular lesions. (D) Category I ulcers (less than 5 cm in widest diameter).

References

    1. Hong H, Demangel C, Pidot SJ, Leadlay PF, Stinear T. Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria. Nat Prod Rep. 2008;14:447–454. doi: 10.1039/b803101k.
    1. Adusumilli S, Mve-Obiang A, Sparer T, Meyers W, Hayman J, Small PL. Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo. Cell Microbiol. 2005;14:1295–1304. doi: 10.1111/j.1462-5822.2005.00557.x.
    1. Coutanceau E, Marsollier L, Brosch R, Perret E, Goossens P, Tanguy M, Cole ST, Small PL, Demangel C. Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell Microbiol. 2005;14:1187–1196. doi: 10.1111/j.1462-5822.2005.00546.x.
    1. Coutanceau E, Decalf J, Martino A, Babon A, Winter N, Cole ST, Albert ML, Demangel C. Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J Exp Med. 2007;14:1395–1403. doi: 10.1084/jem.20070234.
    1. Pahlevan AA, Wright DJ, Andrews C, George KM, Small PL, Foxwell BM. The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. J Immunol. 1999;14:3928–3935.
    1. Torrado E, Adusumilli S, Fraga AG, Small PL, Castro AG, Pedrosa J. Mycolactone-mediated inhibition of tumour necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection. Infect Immun. 2007;14:3979–3988. doi: 10.1128/IAI.00290-07.
    1. Stinear TP, Mve-Obiang A, Small PL, Frigui W, Pryor MJ, Brosch R, Jenkin GA, Johnson PD, Davies JK, Lee RE, Adusumilli S, Garnier T, Haydock SF, Leadlay PF, Cole ST. Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci U S A. 2004;14:1345–1349. doi: 10.1073/pnas.0305877101.
    1. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, Lee R, Small PL. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science. 1999;14:854–857. doi: 10.1126/science.283.5403.854.
    1. Dobos KM, Small PL, Deslauriers M, Quinn FD, King CH. Mycobacterium ulcerans cytotoxicity in an adipose cell model. Infect Immun. 2001;14(11):7182–7186. doi: 10.1128/IAI.69.11.7182-7186.2001.
    1. Bozzo C, Tiberio R, Graziola F, Pertusi G, Valente G, Colombo E, Small PL, Leigheb G. A Mycobacterium ulcerans toxin, mycolactone, induces apoptosis in primary human keratinocytes and HaCaT cells. Microbes Infect. 2010;14(14–15):1258–1263.
    1. Sarfo FS, Phillips RO, Rangers B, Mahrous EA, Lee RE, Tarelli E, Asiedu KB, Small PL, Wansbrough-Jones MH. Detection of Mycolactone A/B in Mycobacterium ulcerans-infected human tissues. PLoS Negl Trop Dis. 2010;14:e325.
    1. Simmonds RE, Lali FV, Smallie T, Small PL, Foxwell BM. Mycolactone inhibits monocyte cytokine production by a posttranscriptional mechanism. J Immunol. 2009;14(4):2194–2202. doi: 10.4049/jimmunol.0802294.
    1. Guenin-Macé L, Carrette F, Asperti-Boursin F, Le Bon A, Caleechurn L, Di Bartolo V, Fontanet A, Bismuth G, Demangel C. Mycolactone impairs T cell homing by suppressing microRNA control of L-selectin expression. Proc Natl Acad Sci U S A. 2011;14(31):12833–12838. doi: 10.1073/pnas.1016496108.
    1. Sarfo FS, Phillips R, Asiedu K, Ampadu E, Bobi N, Adentwe E, Lartey A, Tetteh I, Wansbrough-Jones M. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother. 2010;14:3678–3685. doi: 10.1128/AAC.00299-10.
    1. Sarfo FS, Converse PJ, Almeida DV, Zhang J, Robinson C, Wansbrough-Jones M, Grosset JH. Microbiological, histological, immunological and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease. PLoS Negl Trop Dis. 2013;14(3):e2101. doi: 10.1371/journal.pntd.0002101.
    1. Phillips RO, Sarfo FS, Osei-Sarpong F, Boateng A, Tetteh I, Lartey A, Adentwe E, Opare W, Asiedu KB, Wansbrough-Jones M. Sensitivity of PCR targeting Mycobacterium ulcerans by use of fine-needle aspirates for diagnosis of Buruli ulcer. J Clin Microbiol. 2009;14:924–926. doi: 10.1128/JCM.01842-08.
    1. Marsollier L, Brodin P, Jackson M, Kordulakova J, Tafelmeyer P, Carbonnelle E, Aubry J, Milon G, Legras P, Andre JP, Leroy C, Cottin J, Guilou ML, Reysset G, Cole ST. Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis. PLoS Pathog. 2007;14(5):e62. doi: 10.1371/journal.ppat.0030062.
    1. Phillips RO, Sarfo FS, Abass MK, Abotsi J, Tuah W, Forson M, Amoako YA, Thompson W, Asiedu K, Wansbrough-Jones M. Clinical and bacteriological efficacy of combination of rifampicin and streptomycin for 2 weeks followed by rifampicin and clarithromycin for 6 weeks for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother. In press article. In press article.
    1. Beissner M, Symank D, Phillips RO, Amoako YA, Awua-Boateng NY, Sarfo FS, Jansson M, Huber KL, Herbinger KH, Battke F, Loscher T, Ohene A, Bretzel G. Detection of viable Mycobacterium ulcerans in clinical samples by a novel combined 16S rRNA reverse transcriptase/IS2404 real-time qPCR assay. PLoS Negl Trop Dis. 2012;14(8):e1756. doi: 10.1371/journal.pntd.0001756.
    1. Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, Phillips R, Evans M, Ofori-Adjei D, Klustse E, Owusu-Boateng J, Amedofu GK, Awuah P, Ampadu E, Amofah G, Asiedu K, Wansbrough-Jones M. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother. 2005;14:3182–3186. doi: 10.1128/AAC.49.8.3182-3186.2005.
    1. Phillips RO, Sarfo FS, Nana B, Abass KM, Opare W, Amoako Y, Adentwe E, Fleischer B, Adjei O, Asiedu K, Wansbrough-Jones M. Clinical and bacteriological response of Buruli ulcer patients in Ghana to treatment with rifampicin streptomycin for 7 days per week for 8 weeks compared with rifampicin-streptomycin for 2 weeks followed by rifampicin and clarithromycin for 6 weeks. WHO Annual meeting on Buruli ulcer. 2010. pp. 70–71. .
    1. Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, Tuah W, Awua-Boateng NY, Ampadu EO, Siegmund V, Schouten JP, Adjei O, Bretzel G, van der Werf TS. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet. 2010;14(9715):664–672. doi: 10.1016/S0140-6736(09)61962-0.
    1. Gronberg A, Zettergren L, Bergh K, Stahle M, Heilborn J, Angeby K, Small PL, Akuffo H, Britton S. Antioxidants protect keratinocytes against M. ulcerans mycolactone cytotoxicity. PLoS One. 2010;14(11):e13839. doi: 10.1371/journal.pone.0013839.
    1. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008;14(5):585–601. doi: 10.1111/j.1524-475X.2008.00410.x.
    1. Guenin-Macé L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong H, Leadlay PF, Danckaert A, Ruf MT, Mostowy S, Zurzolo C, Bousso P, Chretien F, Carlier MF, Demangel C. Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. J Clin Invest. 2013;14(4):1501–1512. doi: 10.1172/JCI66576.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться